In the American Association for Cancer Research (AACR) meeting 2016,
Martine Piccart, MD, PhD, of the Jules Bordet Institute in Brussels,
Belgium said that use of the gene assay was associated with a 46%
reduction in prescriptions for chemotherapy among the 3,348 high-risk
patients and 14% reduction for all 6,648 patients in the study. The meeting coverage was published in the Medpage Today on 22.04.2016.
Patients at high clinical/pathologic risk but low risk by the 70-gene MammaPrint assay
had a 5-year distant metastasis-free survival (DMFS) of 94.4% without
chemotherapy versus 95.9% with chemotherapy, a difference that did not
reach statistical significance (HR 0.78, 95% CI 0.50-1.21).
In patients with a low clinical risk but high genetic risk, the 5-year DMFS was 95% to 96% with or without chemotherapy.
As compared to standard clincopathological classification, MammaPrint re-stratified 20% of Clinical High Risk patients to Low risk. 97% of this Low Risk patient group which primarily chose to forgo chemotherapy, were disease free at 5 years.
The first ever prospective clinical study for a breast cancer recurrence assay, RASTER (MicroarRAy PrognoSTics in Breast CancER) was published in 2013.
"The MammaPrint FFPE (Formalin Fixed Paraffin Embedded) tissue test has been approved by the FDA."
It confirmed the utility of the MammaPrint (Agendia) 70-gene signature to identify those breast cancer patients that may safely forgo chemotherapy.
 |
| English: Validation chart for Agendia's MammaPrint Assay, part of the Symphony Breast Cancer Suite (Photo credit: Wikipedia) |
In patients with a low clinical risk but high genetic risk, the 5-year DMFS was 95% to 96% with or without chemotherapy.
As compared to standard clincopathological classification, MammaPrint re-stratified 20% of Clinical High Risk patients to Low risk. 97% of this Low Risk patient group which primarily chose to forgo chemotherapy, were disease free at 5 years.
The first ever prospective clinical study for a breast cancer recurrence assay, RASTER (MicroarRAy PrognoSTics in Breast CancER) was published in 2013.
"The MammaPrint FFPE (Formalin Fixed Paraffin Embedded) tissue test has been approved by the FDA."
It confirmed the utility of the MammaPrint (Agendia) 70-gene signature to identify those breast cancer patients that may safely forgo chemotherapy.
...
Click here to Subscribe news feed from "Clinicianonnet; so that you do not miss out anything that can be valuable to you !!
...
Posts
